IP Library Patent Application 17771195
Patent Application
App. No. 17/771,195

(+)-TRANS TETRAHYDROCANNABINOL ((+)-TRANS-THC) FOR USE AS A MEDICAMENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/771,195
Abstract

The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (−)-trans-tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (+)-trans tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (−)-trans-THC. The cannabinoid (+)-trans-THC has been found to occur in low concentrations in particular cannabis plant strains. Furthermore, the cannabinoid can be produced by synthetic means.

Claims (11)

1 . (+)-trans tetrahydrocannabinol ((+)-trans-THC) for use as a medicament.

2 . (+)-trans-THC for use according to claim 1 , wherein the (+)-trans-THC is in the form of a plant extract.

3 . (+)-trans-THC for use according to claim 2 , wherein the (+)-trans-THC is in the form of a highly purified plant extract.

4 . (+)-trans-THC for use according to claim 3 , wherein the (+)-trans-THC comprises at least 80% (w/w) (+)-trans-THC.

5 . (+)-trans-THC for use according to claim 3 , wherein the (+)-trans-THC comprises at least 95% (w/w) (+)-trans-THC.

6 . (+)-trans-THC for use according to claim 1 , wherein the (+)-trans-THC is in the form of a synthetic compound.

7 . (+)-trans-THC for use according to any of the preceding claims, wherein the dose of (+)-trans-THC is greater than 100 mg/kg/day.

8 . (+)-trans-THC for use according to any of the preceding claims, wherein the dose of (+)-trans-THC is less than 100 mg/kg/day.

9 . A composition for use as a medicament comprising (+)-trans-tetrahydrocannabinol ((+)-trans-THC) and one or more pharmaceutically acceptable excipients.

10 . (+)-trans tetrahydrocannabinol ((+)-trans-THC) for use in the treatment of pain.

11 . A process for the preparation of (+)-trans tetrahydrocannabinol ((+)-trans-THC).

Assignments (3)
CHANGE OF NAME Recorded Feb 2, 2026
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 073658/0457 →
SECURITY AGREEMENT Recorded Jul 26, 2024
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2022
From: GUY, GEOFFREY; KNAPPERTZ, VOLKER; WHALLEY, BENJAMIN; WOOLLEY-ROBERTS, MARIE
To: GW RESEARCH LIMITED
Reel/Frame 061111/0677 →